Latest Communications

18 January 2012
APR Applied Pharma Research s.a. (“APR”), Labtec GmbH (“Labtec”) and Norgine BV (“Norgine”) announce the signature of an exclusive licensing agreement under which Norgine will market and distribute Setofilm™ Ondansetron Oral Dispersible Film (“ODF”), in Europe and selected non-European countries.

12 July 2011
MonoSol Rx Announces Availability of Zuplenz® Oral Soluble Film for Licensing to New Commercialization Partners

13 June 2011
APR Applied Pharma Research s.a. and Labtec GmbH announce Ondansetron Oral Dispersible Film (“ODF”) is now available for licensing in Europe and selected non European countries, after having received marketing authorization in most countries of Europe.


The Innovation

Our patented Nano-Technology electrolytic process enables production of Pure and Stable HClO (Hypoclorous Acid) in a liquid carrier where all the most important parameters are balanced and optimized in order to obtain one of the best formulation in termsof Efficacy and Safety so maximizing its disinfectant and tissue regenerating properties. Interactive link with film of the technology.

PIPE LINE BIO'N

> acne
> eye care
> wound healing

Healthcare Market Potential

HClO is produced by human immune system as protective agent against infectious pathogens, including bacteria, viruses, yeasts and some fungi and it is also one of the primary driver in any tissue regeneration, wound healing process.



Scientific Development Status

Effective and Safe use of HClO for any therapeutical application in humans is strictly dependent on PH, ORP and stability. Bio'n presents a very low PH (below 3), a very high ORP (higher than 1'100 mv) and a good stability for 24 month. Bio'n is under investigation in the following target area: eye injuries , eye infection, chronic and acute infected wounds and acne but other applications of the product are possible. The first tests on the Product showed much promising results.



Search results